A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

NCT05436912 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Hepatic Impairment

Interventions

DRUG: Selpercatinib

Sponsor

Eli Lilly and Company

Collaborators

[object Object]